cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. I. Distribution within the central nervous system after intravenous and intracarotid infusion - PubMed (original) (raw)

Comparative Study

doi: 10.1007/BF01324836.

Affiliations

• PMID: 8410144
• DOI: 10.1007/BF01324836

Comparative Study

cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. I. Distribution within the central nervous system after intravenous and intracarotid infusion

H Nakagawa et al. J Neurooncol. 1993 Apr.

Abstract

The distribution of cis-diamminedichloroplatinum (CDDP) was studied in 23 patients undergoing surgical resection of brain tumors metastatic from lung cancer. CDDP (100 mg/m2) was administered intravenously (i.v.) or intra-arterially (IA) at the time of surgery, and various fluids and tissues were sampled for measurement of drug concentration. Comparison of the two routes of administration disclosed that the plasma level was slightly lower after IA than after i.v. infusion, whereas there was no difference between the two routes in terms of drug diffusion into the brain tissue adjacent to the tumor. However, IA administration resulted in an intratumoral drug concentration twice as high as that achieved with i.v. infusion. The tumor:plasma and tumor:adjacent brain ratios of drug concentration after IA injection were also twice those measured after i.v. administration. The distribution pattern of CDDP is characteristic of water-soluble agents. All patients experienced tolerable nausea and vomiting. Creatinine clearance was moderately reduced in ten cases, but no serious renal toxicity was observed. Seizures occurred postoperatively in nine patients. Infrequent side effects were myelosuppression, ototoxicity, and postoperative intracranial bleeding. All adverse effects disappeared with conservative treatment or no intervention.

PubMed Disclaimer

Similar articles

• [Distribution of cis-diamminedichloroplatinum in patients with metastatic brain tumors after intravenous or intracarotid administration].
  Nakagawa H, Fujita T, Izumoto S, Kubo S, Nakajima Y, Turuzono K. Nakagawa H, et al. Gan To Kagaku Ryoho. 1991 Jan;18(1):103-9. Gan To Kagaku Ryoho. 1991. PMID: 1987891 Japanese.
• Pharmacokinetic study of selective continuous internal carotid CDDP infusion in malignant brain tumors.
  Seiki Y, Shibata I, Terao H, Kudo M, Noguchi T. Seiki Y, et al. Neurol Med Chir (Tokyo). 1991 Nov;31(11):695-701. doi: 10.2176/nmc.31.695. Neurol Med Chir (Tokyo). 1991. PMID: 1723156
• cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. II: Clinical effects.
  Nakagawa H, Fujita T, Izumimoto S, Miyawaki Y, Kubo S, Nakajima Y, Tsuruzono K, Kodama K, Higashiyama M, Doi O, et al. Nakagawa H, et al. J Neurooncol. 1993 Apr;16(1):69-76. doi: 10.1007/BF01324837. J Neurooncol. 1993. PMID: 8410145
• [Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer].
  Nakagawa H, Yamada M, Hagiwara Y, Kanayama T, Iwatsuki, Moriuchi S. Nakagawa H, et al. No Shinkei Geka. 1997 Mar;25(3):215-23. No Shinkei Geka. 1997. PMID: 9058428 Review. Japanese.

Cited by

• Which drug or drug delivery system can change clinical practice for brain tumor therapy?
  Siegal T. Siegal T. Neuro Oncol. 2013 Jun;15(6):656-69. doi: 10.1093/neuonc/not016. Epub 2013 Mar 15. Neuro Oncol. 2013. PMID: 23502426 Free PMC article. Review.
• Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.
  Doolittle ND, Muldoon LL, Culp AY, Neuwelt EA. Doolittle ND, et al. Adv Pharmacol. 2014;71:203-43. doi: 10.1016/bs.apha.2014.06.002. Epub 2014 Aug 22. Adv Pharmacol. 2014. PMID: 25307218 Free PMC article. Review.
• Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors.
  Sarin H. Sarin H. J Transl Med. 2009 Sep 1;7:77. doi: 10.1186/1479-5876-7-77. J Transl Med. 2009. PMID: 19723323 Free PMC article. Review.
• Synergistic effect of cisplatin and synchrotron irradiation on F98 gliomas growing in nude mice.
  Ricard C, Fernandez M, Requardt H, Wion D, Vial JC, Segebarth C, van der Sanden B. Ricard C, et al. J Synchrotron Radiat. 2013 Sep;20(Pt 5):777-84. doi: 10.1107/S0909049513016567. Epub 2013 Jul 3. J Synchrotron Radiat. 2013. PMID: 23955042 Free PMC article.
• Tissue concentration of systemically administered antineoplastic agents in human brain tumors.
  Pitz MW, Desai A, Grossman SA, Blakeley JO. Pitz MW, et al. J Neurooncol. 2011 Sep;104(3):629-38. doi: 10.1007/s11060-011-0564-y. Epub 2011 Mar 12. J Neurooncol. 2011. PMID: 21400119 Free PMC article. Review.

References

1. 1. Neurosurgery. 1983 Sep;13(3):230-3 - PubMed
2. 1. Cancer Treat Rep. 1983 Nov;67(11):1035-7 - PubMed
3. 1. J Neurooncol. 1988 Sep;6(2):157-68 - PubMed
4. 1. Cancer Res. 1982 Jun;42(6):2474-9 - PubMed
5. 1. Cancer Res. 1989 Apr 1;49(7):1877-81 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information